久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • MedDay Announces Full Patient Enrollment for MD1003 Trial November 10, 2018
    MedDay Pharmaceuticals announced full enrollment of SPI2, a phase III clinical trial designed to confirm the potential of its investigational drug MD1003 in progressive MS as shown in MS-SPI phase III trial.
PharmaSources Customer Service